Ndv-3A
Staphylococcus Aureus
NovaDigm Therapeutics, Inc.vaccinePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Staphylococcus Aureus cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TEFIBAZUMAB Bristol-Myers Squibb | Phase 2 | NR |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →